{"product_id":"bway-pestle-analysis","title":"(BWAY) BrainsWay Ltd. PESTLE Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to Market Insight Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis BrainsWay Ltd. PESTLE Analysis shows how political, economic, social, technological, legal, and environmental forces affect the company and why it matters for strategy or investment; the page includes a real preview of the report so you can judge style and depth, and purchasing the full version delivers the complete, ready-to-use company-specific analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePolitical factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIsrael-headquartered, global market exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBrainsWay Ltd., headquartered in Jerusalem, sells in the United States, Europe, Israel, and other markets, so it faces policy risk in at least 4 regions at once. Cross-border rules on imports, medical devices, and reimbursement can slow hospital adoption, while mental health funding directly affects demand. Israel’s geopolitical risk can also disrupt logistics and weigh on investor sentiment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic funding for mental health treatment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBrainsWay sells to hospitals and medical centers that often depend on government healthcare budgets, so public mental health funding directly shapes demand. The WHO says governments still spend about 2% of health budgets on mental health, with high-income countries averaging about $65 per person, so funding gaps can slow installations and patient access. Policy that favors outpatient care and early intervention can speed adoption of non-invasive treatments like BrainsWay's devices.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory oversight in major markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBrainsWay Ltd. sells into tightly regulated healthcare markets in the United States and Europe, where clearance, reimbursement, and post-market monitoring can slow new indication launches. In 2024, revenue was $44.6 million, so even small delays in FDA and EU review can matter. Political focus on patient safety and health technology assessment also shapes payer coverage, while stable rules support long Deep TMS product cycles.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHealthcare procurement by public institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHealthcare procurement by public institutions can slow BrainsWay Ltd. sales because hospitals and psychiatric centers often buy through centralized, budget-led processes. That means one tender can cover many sites, but delayed capital approvals can also push revenue conversion by one or more quarters.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCentral buying creates long sales cycles.\u003c\/li\u003e\n\u003cli\u003ePublic tenders can open multi-site access.\u003c\/li\u003e\n\u003cli\u003eBudget delays can defer revenue recognition.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInternational trade and market access policy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBrainsWay sells across borders, so tariffs, customs checks, and medical device import rules can directly affect delivery time and compliance cost. Trade friction between regions can slow distributor onboarding and make hospital access harder in smaller overseas markets. Stable trade ties help BrainsWay add new hospital systems and expand channel coverage faster.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTariffs and customs raise landed cost.\u003c\/li\u003e\n\u003cli\u003eImport rules can delay shipments.\u003c\/li\u003e\n\u003cli\u003eStable policy supports new distributors.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolicy Risk and Mental Health Funding Could Shape BrainsWay’s Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBrainsWay Ltd. faces political risk in the U.S., Europe, Israel, and other markets, so FDA, EU, and import rules can delay device launches and shipments. Public mental health budgets matter too: WHO says governments spend about 2% of health budgets on mental health, with high-income countries near $65 per person.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$44.6M, 2024\u003c\/td\u003e\n\u003ctd\u003ePolicy delays can hit sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMental health spend\u003c\/td\u003e\n\u003ctd\u003e~2% of health budgets\u003c\/td\u003e\n\u003ctd\u003eFunding shapes demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eExamines how Political, Economic, Social, Technological, Environmental, and Legal forces shape BrainsWay Ltd.’s opportunities and risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise BrainsWay Ltd. PESTLE snapshot that simplifies external risk review and speeds up strategy discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eCites primary industry reports, clinical trial registries, regulatory filings, and financial statements to speed due diligence and let investors verify BrainsWay claims quickly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEconomic factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital spending by hospitals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBrainsWay Ltd. sells clinic equipment, so hospital capital budgets directly shape demand. In 2025, U.S. policy rates stayed at 4.25%-4.50%, and tighter credit made it harder for clinics to fund new devices. When budgets improve, hospitals are more willing to add treatment systems, but slower economies can push sales cycles out by months.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReimbursement-driven demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBrainsWay Ltd.'s demand is reimbursement-led: a typical TMS course can take 20-30 sessions, so payer coverage directly shapes patient volume and clinic use. Better insurance terms lower out-of-pocket cost and lift adoption, while weak or unclear coverage can delay starts even when clinical need is high. Revenue growth still hinges on payer acceptance in core U.S. and ex-U.S. markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal healthcare spending growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGlobal health spending keeps lifting demand for BrainsWay Ltd.'s therapies: U.S. national health spending is projected to rise 7.5% in 2025 to $6.8 trillion, while WHO says people aged 60+ will reach 1.4 billion by 2030. More budget means more room for depression, OCD, smoking cessation, and other neurostimulation use. In tighter spending cycles, device buys and clinic growth can slow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCurrency exposure across regions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBrainsWay Ltd. sells across the U.S., Europe, and Israel, so revenue lands in USD, EUR, and ILS. A stronger U.S. dollar can cut the translated value of overseas sales, while FX swings can also move margins and operating costs. That makes distributor pricing and 2025–2026 forecast plans harder to lock in.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e3 core currencies: USD, EUR, ILS\u003c\/li\u003e\n\u003cli\u003eFX swings hit revenue and margins\u003c\/li\u003e\n\u003cli\u003eUSD strength can lower translated sales\u003c\/li\u003e\n\u003cli\u003ePricing and forecasts need constant resets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCost of clinical adoption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBrainsWay Ltd.'s non-invasive neurostimulation faces upfront clinic costs: device purchase, staff training, and workflow changes. A standard acute course can run 20-30 sessions, so providers compare that setup cost with lower-cost drug therapy and other options. Adoption improves when the device lifts throughput and cuts longer-term care spend.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUpfront device and setup costs matter most\u003c\/li\u003e\n\u003cli\u003e20-30 sessions shape clinic economics\u003c\/li\u003e\n\u003cli\u003eClear ROI supports psychiatric and hospital use\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrainsWay Faces Rate, Reimbursement, and FX Headwinds\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBrainsWay Ltd. depends on clinic budgets, payer coverage, and FX. In 2025, U.S. rates stayed 4.25%-4.50%, which kept financing tight for device buys. U.S. health spending is projected to reach $6.8 trillion in 2025, but slower reimbursement or a strong USD can still delay orders and cut translated sales.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003e2025\/2026 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRates\u003c\/td\u003e\n\u003ctd\u003e4.25%-4.50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. health spend\u003c\/td\u003e\n\u003ctd\u003e$6.8T in 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFX risk\u003c\/td\u003e\n\u003ctd\u003eUSD, EUR, ILS exposure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eBrainsWay Ltd. PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact BrainsWay Ltd. PESTLE analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSociological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRising mental health awareness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRising mental health awareness supports demand for depression and anxiety care, and the World Health Organization says 1 in 8 people live with a mental disorder. Patients are more willing to seek care now, so non-drug therapies like BrainsWay Ltd.'s treatments can reach a wider market.\u003c\/p\u003e\n\u003cp\u003eAwareness campaigns also reduce stigma, which can lift diagnosis and referral rates. That matters because depression is a leading cause of disability worldwide, and more treatment-seeking can turn unmet need into paid demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePreference for non-invasive treatment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBrainsWay Ltd.’s non-invasive Deep TMS fits patient demand to avoid surgery and the side effects of systemic drugs, which helps in treatment-resistant depression and OCD cases. Office-based sessions also suit patients who want outpatient care, and that ease can lift adoption by psychiatrists and hospital centers. This matters in a large market: depression affects about 280 million people worldwide, and roughly 30% do not respond well to first-line treatment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh burden of chronic psychiatric illness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBrainsWay Ltd. benefits from the high burden of chronic psychiatric illness: WHO says about 1 in 8 people worldwide lives with a mental disorder, and depression affects roughly 280 million people. Major depressive disorder, OCD, PTSD, and addiction often need repeated care, so symptom persistence keeps demand high for non-drug therapies like deep TMS and accessible, evidence-based treatment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAgeing and neurodegenerative demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAgeing lifts demand for BrainsWay Ltd. beyond psychiatry: WHO estimates about 55 million people live with dementia worldwide, Parkinson’s affects over 10 million, and MS and stroke survivors also need long rehab support. As the global 65+ population keeps rising, these disorders become more common, so BrainsWay’s non-invasive therapy stays relevant for function and quality of life.\u003c\/p\u003e\n\u003cp\u003eThat broadens BrainsWay Ltd.’s clinical base and supports use in Alzheimer’s disease, MS, post-stroke rehab, and Parkinson’s care. The message is simple: more older patients means a bigger need for therapies that help people keep moving, thinking, and living independently.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e55 million dementia cases worldwide\u003c\/li\u003e\n\u003cli\u003e10+ million Parkinson’s cases worldwide\u003c\/li\u003e\n\u003cli\u003eAgeing expands neurological demand\u003c\/li\u003e\n\u003cli\u003eQuality-of-life care supports adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSmoking cessation and lifestyle-related care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSmoking cessation is a large behavior-health need: WHO says tobacco still causes over 8 million deaths a year, and U.S. adult smoking was 11.6% in 2022, keeping demand for non-drug support high. For BrainsWay Ltd., this fits prevention-led care and can widen use of clinic-based, lifestyle-focused treatment.\u003c\/p\u003e\n\u003cp\u003eAs more patients and providers seek non-pharmacological help, broader wellness pathways can lift treatment volumes beyond depression and OCD. This can support repeat visits, referrals, and payer interest in lower-risk care.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh unmet need keeps demand durable\u003c\/li\u003e\n\u003cli\u003eNon-drug care fits prevention trends\u003c\/li\u003e\n\u003cli\u003eMore wellness use can raise volumes\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRising Mental Health Needs Fuel Demand for BrainsWay’s Noninvasive Deep TMS\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRising mental health awareness and lower stigma support BrainsWay Ltd.'s demand, with WHO saying 1 in 8 people live with a mental disorder and depression affecting about 280 million. Patients also want non-drug, non-invasive care, so Deep TMS fits outpatient use and treatment-resistant cases. Ageing and chronic illness keep the need high in neurology too.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDriver\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMental disorders\u003c\/td\u003e\n\u003ctd\u003e1 in 8 people\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDepression\u003c\/td\u003e\n\u003ctd\u003e280 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTobacco deaths\u003c\/td\u003e\n\u003ctd\u003e8M+ yearly\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eTechnological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatented Deep TMS platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBrainsWay Ltd.’s Deep TMS platform uses an H-coil design to reach deeper and broader brain regions than standard coils, which is its main edge in non-invasive brain stimulation. The same device family supports multiple cleared indications, so one platform can serve more than one market without a full product reset. That technology-led model is central to BrainsWay Ltd.’s commercial pitch and helps support higher-value clinical adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMulti-indication clinical expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBrainsWay Ltd.’s Deep TMS platform spans psychiatric and neurological uses, so one system can support multiple care paths. Each new clearance or positive study boosts the value of its installed base and widens commercial optionality. That matters because clinical versatility is a key medtech edge: more evidence can mean more sites, more patients, and longer device use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinic-based device workflow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBrainsWay’s clinic workflow hinges on trained operators, clear treatment protocols, and high device uptime; a stalled system can cut same-day capacity and hurt clinic economics. Simple setup and reliable hardware help adoption, while software updates and session tracking support standardized care across its FDA-cleared deep TMS platform.\u003c\/p\u003e\n\u003cp\u003eStrong technical support also matters for retention, because clinics need fast fixes to keep sessions on schedule and patients on plan.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eResearch and trial dependence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBrainsWay Ltd.’s growth still depends on research and trial data because neurostimulation buyers want proof, not just clearance. Strong peer-reviewed results and real-world outcomes help win physician trust and payer coverage, while weak evidence can slow uptake even when the device is on the market.\u003c\/p\u003e\n\u003cp\u003eThis matters in new markets, where validation often decides whether a clinic adopts the system. In this field, the trial record is part of the product.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMore data speeds adoption.\u003c\/li\u003e\n\u003cli\u003ePeer review builds confidence.\u003c\/li\u003e\n\u003cli\u003ePayer access needs proof.\u003c\/li\u003e\n\u003cli\u003eWeak evidence slows sales.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDigital integration potential\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eModern neuropsychiatry is moving toward digital screening, remote symptom tracking, and outcomes tracking, so BrainsWay Ltd. can gain from tighter links to electronic medical records and clinic software. Better data capture makes each treatment easier to track, compare, and report, which also helps clinics prove value to payers and patients.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFaster patient onboarding\u003c\/li\u003e\n\u003cli\u003eCleaner outcome reporting\u003c\/li\u003e\n\u003cli\u003eStronger follow-up after treatment\u003c\/li\u003e\n\u003cli\u003eBetter sales proof for clinics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eStronger digital connectivity can also lift post-treatment follow-up and support repeat use, since clinic teams can see response data faster and act sooner.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrainsWay’s Deep TMS Edge Hinges on Uptime and Data\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBrainsWay Ltd.’s tech edge is Deep TMS: an H-coil design that reaches broader brain regions and supports multiple cleared uses on one platform. That helps clinic throughput, but growth still depends on strong trial data, fast software updates, and reliable uptime so sites can track outcomes and keep sessions on schedule.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003e2025\/2026 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore tech\u003c\/td\u003e\n\u003ctd\u003eDeep TMS H-coil platform\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial value\u003c\/td\u003e\n\u003ctd\u003eOne device, multiple indications\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperational need\u003c\/td\u003e\n\u003ctd\u003eHigh uptime, fast support\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eData need\u003c\/td\u003e\n\u003ctd\u003eOutcome tracking\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eLegal factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical device regulatory clearance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBrainsWay Ltd. must keep device clearances in the U.S., Europe, Israel, and other markets, because each approval sets the exact indications it can sell. FDA and CE changes can narrow or expand claims, and even a labeling shift can change revenue upside by limiting who can be treated. Ongoing quality and post-market compliance are not optional; a lapse can pause commercialization and delay new launches.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical evidence and claims control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBrainsWay Ltd. must keep every marketing claim tied to clinical data, especially across depression, OCD, addiction, and neurological uses. Regulators can challenge unsupported efficacy language, so strong trial files and clean endpoint records are a legal shield. Across these 4 main indication buckets, precise evidence control lowers the risk of label, ad, or disclosure disputes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eData privacy and patient records\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBrainsWay Ltd. handles protected health information in clinics, so HIPAA in the U.S. and GDPR in Europe drive strict controls for software, follow-up data, and patient records. HIPAA civil penalties can reach $2.1 million per year for repeated violations, while GDPR fines can hit €20 million or 4% of global annual turnover. Any breach can trigger claims, lost trust, and lower clinic adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eIntellectual property protection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBrainsWay’s differentiated neurostimulation platform relies on patents and proprietary know-how, so IP protection is central to defending pricing and share. Patent disputes can hit valuation fast; for example, BrainsWay reported FY2025 revenue of about $46 million, so even small IP shocks can matter. Strong IP also helps support licensing deals and global rollout in regulated markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatents protect the core platform\u003c\/li\u003e\n\u003cli\u003eDisputes can pressure valuation\u003c\/li\u003e\n\u003cli\u003eIP supports licensing and expansion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eProduct liability and safety obligations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBrainsWay Ltd. faces strict product liability risk because its non-invasive brain stimulation devices must meet safety, labeling, and adverse-event reporting duties. Hospitals and medical centers expect clear use instructions and risk controls, and missed protocol steps can turn a clinical issue into legal exposure.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eSafety compliance supports long-term sales.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eProtocol drift raises liability risk fast.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eClear labeling helps hospital adoption.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrainsWay’s Legal Risks Could Quickly Dent a $46M Revenue Base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBrainsWay Ltd.’s legal risk is tied to device clearances, claims, and data rules; any FDA, CE, HIPAA, or GDPR lapse can slow sales or trigger fines. FY2025 revenue was about $46 million, so even a small legal hit can matter. Patent protection also matters because it supports pricing and global rollout.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLegal factor\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2025 revenue\u003c\/td\u003e\n\u003ctd\u003eAbout $46 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHIPAA penalty\u003c\/td\u003e\n\u003ctd\u003eUp to $2.1 million per year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGDPR fine\u003c\/td\u003e\n\u003ctd\u003e€20 million or 4% of turnover\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEnvironmental factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow chemical waste treatment model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBrainsWay’s device-based therapy avoids on-site drug manufacturing, so it can cut chemical waste versus medication-heavy care paths. The model still uses power and equipment, but the footprint is relatively clean, with 0 routine drug compounding at the clinic level. That can appeal to sustainability-focused healthcare buyers in 2025–2026.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElectric power usage in clinics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBrainsWay Ltd.’s dTMS systems need steady electricity and a controlled room, so power outages can stop care fast. U.S. hospitals spent about $10.8 billion on electricity in 2024, making energy efficiency a real cost issue. Clinics also face tougher emissions targets, with many health systems aiming for net-zero by 2050, so low-energy equipment can help procurement.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElectronic equipment lifecycle\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBrainsWay’s hardware creates lifecycle duties for devices, parts, and spares, so design for repair and longer component life matters. The world generated 62 million tonnes of e-waste in 2022, but only 22.3% was formally recycled, which raises end-of-life pressure on manufacturers and distributors. Responsible take-back and recycling can cut disposal risk and lower the environmental footprint of replacement cycles.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGlobal shipping footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBrainsWay Ltd. ships internationally, so freight and packaging add direct emissions and can raise exposure to delays, damage, and border disruption. Maritime shipping alone is about 3% of global CO2 emissions, so long lanes can matter fast. \u003c\/p\u003e\n\u003cp\u003eRegional inventory planning can cut freight intensity by shortening routes and lowering air-freight use, which also reduces packaging waste. Customers and hospital buyers are increasingly asking for lower-impact logistics, so transport choices now affect both cost and brand risk. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGlobal distribution lifts transport emissions.\u003c\/li\u003e\n\u003cli\u003eLong routes increase supply-chain risk.\u003c\/li\u003e\n\u003cli\u003eRegional stock can reduce freight intensity.\u003c\/li\u003e\n\u003cli\u003eLower-impact logistics are a buyer priority.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHealthcare sustainability pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHospitals and medical centers are under growing pressure to report environmental performance, and healthcare is estimated to drive about 4.4% of global net emissions. That pushes procurement teams to favor efficient devices with lower waste, so sustainability can now affect tender scores in Europe and other regulated markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e4.4% of global emissions\u003c\/li\u003e\n\u003cli\u003eLower waste can win tenders\u003c\/li\u003e\n\u003cli\u003eEU buyers face ESG reporting pressure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrainsWay’s Green Edge Still Hinges on E-Waste and Power Use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBrainsWay Ltd. has a lighter waste profile than drug-based care, but it still faces power use, transport emissions, and device end-of-life duties. Healthcare drives about 4.4% of global net emissions, and only 22.3% of 62 million tonnes of e-waste was formally recycled in 2022, so repair, take-back, and regional stock matter.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealthcare emissions\u003c\/td\u003e\n\u003ctd\u003e4.4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eE-waste recycled\u003c\/td\u003e\n\u003ctd\u003e22.3%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal e-waste\u003c\/td\u003e\n\u003ctd\u003e62m tonnes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234096455945,"sku":"bway-pestle-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/bway-pestle-analysis.webp?v=1785713889","url":"https:\/\/dcfanalyst.com\/products\/bway-pestle-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}